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Abstract
Identifying subgroups, which respond differently to a treatment, both in terms of
efficacy and safety, is an important part of drug development. A well-known challenge
in exploratory subgroup analyses is the small sample size in the considered subgroups,
which is usually too low to allow for definite comparisons. In early phase trials this
problem is further exaggerated, because limited or no clinical prior information on the
drug and plausible subgroups is available. We evaluate novel strategies for treatment
effect estimation in these settings in a simulation study motivated by real clinical trial
situations. We compare several approaches to estimate treatment effects for selected
subgroups, employing model averaging, resampling and Lasso regression methods.
Two subgroup identification approaches are employed, one based on categorization
of covariates and the other based on splines. Our results show that naive estimation
of the treatment effect, which ignores that a selection has taken place, leads to bias
and overoptimistic conclusions. For the considered simulation scenarios virtually all
evaluated novel methods provide more adequate estimates of the treatment effect for
selected subgroups, in terms of bias, MSE and confidence interval coverage.
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1 Introduction
Identifying subgroups, which respond differently to treatment, both in terms of efficacy, as
well as safety, is an important part of drug development, see Ruberg & Shen (2015) for
an overview. Consequently subgroup analyses are routinely conducted in different forms
throughout clinical drug development. Methodological differences in the way subgroup
analyses are being conducted exist, depending on when and in what setting they are used.
When there are claims to be made about subgroups in a confirmatory setting in Phase
III trials, a multiple testing strategy is set up and separate hypotheses are used to test the
treatment effect in the subgroup and the overall population (or the subgroup complement),
see for example Bretz et al. (2009) or Glimm & Di Scala (2015) for considerations from a
multiple testing perspective.
In case a drug gets approved, additional post-hoc analyses are performed to investigate
the consistency of the treatment effect, for example in different countries, or according to
other demographic patient characteristics. Alosh et al. (2015) provide an overview of these
analyses from a regulatory perspective.
In this article we will focus on exploratory analyses of subgroups in clinical trials, as
they are performed for example in early phase clinical trials. The aim in this setting is to
investigate, whether patients with different baseline characteristics, such as demographic,
disease-specific or genetic covariates respond differently to treatment. Usually a moder-
ate number of covariates is chosen, based on biological, clinical and pharmacological prior
information and then analysed. If a subgroup is identified in these analyses, further devel-
opment of the new drug could then specifically be targeted on the identified subgroup or
future trials could be planned using an enrichment strategy, recruiting more patients from
the identified subgroup.
This is more challenging than the confirmatory setting, as the sample size in the con-
sidered subgroups in these trials is usually too small to identify small (but possibly still
relevant) differential treatment effects reliably. In addition multiple groups are being looked
at, which leads to a multiplicity/selection problem, in the sense that even if there is no
differential effect, the search/selection itself will lead to finding a subgroup with higher
observed treatment effect, just by chance (see for example Brookes et al. (2004), Wang
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et al. (2007), Fleming (2010), Ruberg & Shen (2015)).
Standard medical statistics practice is to perform subgroup analyses in these settings by
adding the subgroup covariate (usually as a categorical variable) one at a time in the model
as a main effect and as interaction with the treatment. Then the effect of the treatment
by covariate interaction is observed to choose a model/subgroup with the most promising
treatment effect (i.e., where the difference between subgroup and complement is largest).
The main purpose of this article is to compare novel strategies to improve this practice
in realistic simulation scenarios. In particular we evaluate treatment effect estimation after
selection in terms of bias, precision and confidence interval coverage, but we also evaluate
performance characterictics of our subgroup identification methods.
There exists some work on treatment effect estimation in subgroup analysis, but still the
literature is relatively scarce, when it comes to the situation of multiple overlapping sub-
groups. In the situation of non-overlapping subgroups, hierarchical modelling has become
one standard approach to deal with exaggerated treatment effect estimates by a shrinkage
towards the overall mean (see for example Jones et al. (2011), Varadhan & Wang (2016)).
When it comes to overlapping subgroups Sun & Bull (2005) discuss resampling approaches
in the context of genome-wide association studies, a situation which is very similar to the
one discussed here. Foster et al. (2011) compare several different ways to estimate the
treatment effect in an identified subgroup based on resampling. Rosenkranz (2016) also
discusses resampling corrections of treatment effects after a selection has been performed.
Berger et al. (2014) discuss Bayesian model averaging to obtain an implicit adjustment
for the selection. While not explicitly motivated in the context of subgroup analysis, the
Lasso approach proposed by Tibshirani (1996), can also be used to shrink treatment ef-
fect estimates in individual subgroups. In this paper the performance of a variant of the
model averaging approach (based on Bornkamp et al. (2015)) as well as resampling meth-
ods and the Lasso approach are evaluated to obtain corrected treatment effect estimates
for a selected subgroup.
In terms of subgroup identification the categorization of continuous covariates has been
widely criticized (see among others Weinberg (1995) or Royston et al. (2006)), but is
still routinely performed in medical practice. For this purpose, we compare two subgroup
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identification strategies, one based on categorizing continuous covariates, one based on
including continuous covariate effects.
In recent years a number of novel methods for subgroup identification have been devel-
oped based on recursive partitioning (see among many others Su et al. (2009), Lipkovich
et al. (2011), Foster et al. (2011), Berger et al. (2014), Loh et al. (2015)). As their name
suggests, these methods are also based on categorization of covariates to identify subgroups,
but they also allow subgroups to be defined in terms of multiple covariates. In this arti-
cle we will only be concerned with subgroups defined by one covariate, even though most
methods presented can be applied with modifications also in situations, when more than
one covariate defines the subgroup.
The outline of this paper is as follows. In Section 2 we will present the utilized models
and different treatment effect estimates. In Section 3 the setup for the simulation study is
presented. In Sections 4 and 5 we will present the simulation results. Section 6 concludes
the paper with a short discussion.
2 Statistical Methodology
In this section we will present the considered statistical setting, utilized models and different
treatment effect estimation methods.
2.1 General Setting and Notation
Consider a clinical trial with a treatment and a control arm, n patients in total and a
continuous outcome y measured for each patient. Without loss of generality it is assumed
that higher values of the outcome variable are preferable with regards to the patient’s
condition. We assume that this outcome variable is normally distributed, which is the
practically most relevant case, but extensions of the models described here to binary, count
or time-to-event data should be possible as well.
Furthermore we assume there are K continuous covariates, so that for patient i the
k−th covariate value is xik, k = 1, . . . , K and i = 1, . . . , n.
The following linear models are considered for subgroup identification and subgroup
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effect inference. We denote the total number of models by P , where P can be larger than
K, so there can be more models than covariates. Then for p = 1, ..., P each model is of the
general form
Mp : yi ∼ N(µ(p)i , σ2p), i = 1, ..., n,
where µ
(p)
i = β
(p)
0 + h
(p)(xi.) + (β
(p)
1 + g
(p)(xi.))Ti
(1)
In this model Ti denotes whether patient i is in the treatment (Ti = 1) or the control
arm (Ti = 0), xi. = (xi1, ..., xiK)
′
contains the covariates for patient i. h and g are functions
of the covariates, mapping from RK → R1. In many of the cases we consider here, these
function transform only one of the K covariates, so that each of the P models only consider
one covariate at a time. The function h(x) represents prognostic (modifying the response
independent of treatment) and the function g(x) predictive effects (modifying the response
to treatment) of a covariate.
In what follows two different choices for h and g are discussed.
2.2 Choosing the Functions h and g
2.2.1 Step Functions
A standard approach in terms of subgroup analyses is to choose the functions g and h
proportional to step functions of the form 1(c,∞)(x), where c is a cut-off and 1 is the
indicator function. This cut-off splits the trial population into two parts with consequently
different response. Often c is chosen as a quantile of the corresponding covariate vector. In
the following the three quartiles of each covariate are used as cut-offs. Using the quartiles
still allows for a certain amount of flexibility, but the overall population is not partitioned
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into too small parts. In detail this approach results in the following functions g and h:
h(p)(xi.) = β2s
(p)
i and g
(p)(xi.) = β3s
(p)
i ,
where s
(p)
i :=

1(q0.25(x.1),∞)(xi1) for p = 1
1(q0.5(x.1),∞)(xi1) for p = 2
1(q0.75(x.1),∞)(xi1) for p = 3
1(q0.25(x.2),∞)(xi2) for p = 4
...
1(q0.5(x.K),∞)(xiK) for p = P − 1
1(q0.75(x.K),∞)(xiK) for p = P,
.
and qp(x.k) denotes the p−quantile of the kth covariate.
Each of the vectors s(p) = (s
(p)
1 , ..., s
(p)
n )
′
is thus a binary vector, denoting, whether a
patients belongs to a subgroup (i.e. the corresponding covariate is larger than the cut-off)
or not. So each covariate defines three different partitions, which split the trial population
into subgroup and complement. With this approach for transforming covariates there are
thus P = 3 ·K candidate models of the form
Mp : yi ∼ N(µ(p)i , σ2p), i = 1, ..., n
where µ
(p)
i = β
(p)
0 + β
(p)
2 s
(p)
i + (β
(p)
1 + β
(p)
3 s
(p)
i )Ti
(2)
2.2.2 Spline Modelling
Instead of using step functions one can also employ splines to model the effect of covariates,
here natural cubic regression splines will be used (see for example (Hastie et al. 2009,
Chapter 9)). We use
h(p)(xi.) =
L∑
m=1
β
(p)
m+1 · bm(xip)
g(p)(xi.) =
L∑
m=1
β
(p)
L+m+1 · bm(xip),
here b1, ..., bL are the basis functions of a natural cubic spline for L given knots ξ1, ..., ξL.
See Appendix A for how the knots were selected, depending on the total sample size.
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By using these forms of g and h in model (1) one obtains P = K models in total, one
model for each covariate.
Mp : yi ∼ N(µ(p)i , σ2p), i = 1, ..., n,
where µ
(p)
i = β
(p)
0 +
L∑
m=1
β
(p)
m+1 · bm(xip) + (β(p)1 +
L∑
m=1
β
(p)
L+m+1 · bm(xip))Ti.
(3)
Transformations of covariates are often used in practice to obtain more uniformly dis-
tributed covariates (e.g. using a log-transformation for positive measurements). We use
a rank transformation, i.e., instead of using xik per patient, rik = rank(xik)/n will be
used as input to the spline bases, where rank(xik) gives the rank of xik within all values
x1k, . . . , xnk of covariate k. Of course all modelling results can be backtransformed using
the quantile function, if desired. Using this approach the flexibility of the spline will be
higher where the covariate is densely sampled and the flexibility of the spline is reduced
where there are only few data. In our experience this approach improves performance of
the method by reducing the variability of the spline estimate close to the boundaries of the
covariate space.
2.2.3 Obtaining Treatment Effects
We now describe how a treatment effect estimate for an identified subgroup can be obtained
from the two models above. Assume a subgroup of patients has been identified and let S
denote the set of indices (from {1, . . . , n}) corresponding to the patients in this subgroup.
Denote the treatment effect in S by ∆(S). An estimate of ∆(S) can be derived by predicting
the treatment effect for each patient in the subgroup and averaging over all patients in the
subgroup. Using any model Mp from (1) we predict the treatment effect for patient i under
Mp as
δˆ
(p)
i = µˆ
(p)
i|Ti=1 − µˆ
(p)
i|Ti=0 = βˆ
(p)
1 + gˆ
(p)(xi.). (4)
The estimated treatment effect for a subgroup S, under model Mp, is then given by
∆ˆ(p)(S) =
1
|S|
∑
i∈S
δˆ
(p)
i . (5)
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For the model (2) this reduces to
∆ˆ(p)(S) = βˆ
(p)
1 + wβˆ
(p)
3 , (6)
where w = |S ∩S(p)|/|S| and S(p) = {i ∈ {1, ..., n}|s(p)i = 1} is the subgroup investigated in
model Mp. The value w ∈ [0, 1] is measuring the fraction of patients of subgroup S that are
also in subgroup S(p). This simplifies to βˆ
(p)
1 + βˆ
(p)
3 , if S = S
(p) and to βˆ
(p)
1 if S is the com-
plement of S(p). For model (3) one obtains ∆ˆ(p)(S) = βˆ
(p)
1 +
∑L
m=1[βˆL+m+1
1
|S|
∑
i∈S bm(xip)]
as the treatment effect estimate under a given model Mp.
2.3 Subgroup Identification
The focus of this work is treatment effect estimation, so for identification of the subgroup
we used approaches that we think reflect current practice relatively well. The recursive
partitioning methods cited in the introduction would be alternative more elaborate methods
for identification of subgroups, that also allow to identify subgroups defined by more than
one covariate.
For identifying a subgroup, interaction tests on the predictive terms of the models are
employed. We only test the predictive term, because the interest lies in finding subgroups,
that have a better treatment effect than the overall population. Prognostic effects occur
independently of the treatment and don’t influence the treatment effect. For model (2) this
leads to a t-test on the null hypothesis H0 : β3 = 0. For the model (3) a likelihood-ratio
test is performed comparing the models with and without the predictive term g(p)(xi.). In
both scenarios these tests are performed for each of the P submodels. Then the model with
the highest evidence of a differential effect (as measured by the lowest p-value) is identified
as the model for describing a subgroup. When using a step function this approach is
equivalent to selecting the subgroup, where the standardized treatment effect difference is
maximized.
When using step functions picking a model is equivalent to choosing a subgroup, for
splines only the covariate is chosen. In case splines are used, the subgroup definition still
needs to be derived. For consistency a similar criterion will be used for splines as for step
functions to obtain a cut-off value.
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We identified the cut-off, that maximizes the differential treatment effect between the
two resulting subgroups. Assume that covariate p has been identified. We then calculate
a metric for each cut-off from a prespecified set, that splits the patients into the subgroup
S1 = {i ∈ {1, ..., n}|xip > c} and its complement S2 = {i ∈ {1, ..., n}|xip ≤ c}. We use a
metric of the form
Z(S1,c, S2,c) =
|∆ˆ(p)(S1,c)− ∆ˆ(p)(S2,c)|√
V ar[∆ˆ(p)(S1,c)− ∆ˆ(p)(S2,c)]
, (7)
and choose the cut-off c which maximizes this from a set of possible cut-offs c1, ...., cs. In
analogy to subgroup identification using step functions we consider the three quartiles as
possible cut-offs for the chosen covariate.
With both approaches we technically end up with two possible subgroups, left and right
of the identified cut-off. To identify which of those subgroups has the better treatment
effects, the naive estimates (see Section 2.4.1) are compared and the subgroup with the
bigger estimate is then identified as the best subgroup.
The approach in this section chooses the subgroup for which the evidence of a differential
effect between subgroup and complement is largest. An alternative would be to select the
subgroup where the estimated treatment effect difference to the complement is largest (i.e.
ignoring the denominator in Equation (7)). We also considered this approach and will come
back to this in the Discussion in Section 6.
2.4 Treatment Effect Estimation in Subgroups
In this section the different methods for treatment effect estimation will be presented.
Apart from the naive estimation method, all of the following methods try to provide an
adjusted estimate that corrects for the bias, which is introduced through the selection of
a subgroup. Note that all methods can be used based on both models (step functions and
splines) introduced above.
2.4.1 Naive Estimates
For the naive estimates we simply estimate the treatment effect as in (5) from the model
that corresponds to the selected subgroup (when using (2)) or the covariate identified to
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define the subgroup (when using (3)). A naive treatment effect estimator for an identified
subgroup S defined by model Mp is therefore simply
∆ˆnaive(S) := ∆ˆ
(p)(S), (8)
where S = S(p). The variance for these estimates can be derived by observing that this is
an average of linear combinations of maximum likelihood parameter estimates, regardless
of which modeling approach is used. A (1− α)- confidence interval is then given through
[∆ˆnaive(S)± tn−d,1−α
2
√
V ar(∆ˆnaive(S))], (9)
where tn−d,1−α
2
is the (1− α
2
)-quantile of the t-distribution with n−d degrees of freedom and
d is the number of parameters in the model (d = 4 for models (2) and d = 2L+2 for models
(3)). Note that this approach is problematic as the selection process/model uncertainty
is being ignored: Model Mp is utilized as if it was pre-specified and not selected in a
data-driven manner.
2.4.2 Model Averaging
Subgroup identification can be viewed as a model selection: A set of candidate models (=
subgroups) is evaluated and then one is chosen, ignoring the associated model uncertainty.
An alternative is to use model averaging see among many others Draper (1995), Raftery
(1995). The idea of model averaging in the context of treatment effect estimation for
subgroups is that every model Mp can be used to predict a treatment effect for a subgroup
S. Because most covariates do not interact with the treatment, many of these models will
predict a similar treatment effect for the underlying subgroup and complement, which will
both be similar to the overall effect. Depending on the weight of the different models, there
will hence be more or less shrinkage towards the overall effect for a particular subgroup S.
Note that the naive estimates can be seen as a special case of this approach, where one
model is given a model weight of 1 and all others zero. From a model averaging perspective
this naive estimate would thus only be justified if the corresponding model would be much
more likely than any of the other considered models.
Using Bayesian model averaging in the context of subgroup analyses was proposed by
Berger et al. (2014) with a particular focus on subgroup identification and less on treatment
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effect estimation. They used a full Bayesian approach, and also performed model averaging
over the model with no treatment effect and the model with a homogeneous treatment effect.
For the simulations here, we chose to use BIC approximations for the model weights. The
BIC turns out to give similar weights to the ones obtained by a full Bayesian approach,
based on MCMC sampling, but is much faster to calculate. See Bornkamp et al. (2015)
for a more detailed comparison of MCMC versus BIC approximations and inclusion of the
models assuming a homogeneous or no treatment effect in a model averaging approach.
The BIC approximations for posterior model weights are given by
P (Mp|y) ≈ P ∗(Mp|y) = exp(−0.5 ·BIC(Mp))∑P
p′=1 exp(−0.5 ·BIC(Mp′)
.
Note that all models have the same number of parameters here, so that the penalty terms
cancel out and the AIC or just the log-likelihood instead of the BIC would give identical
results.
By using the posterior model weights, estimates for the posterior mean and variance
of the treatment effect of a subgroup S can be obtained by estimating the treatment
effect of this subgroup under all considered models, as described in Section 2.2.3, and then
averaging over all models. The model averaging estimator of the treatment effect is then
the approximation to the posterior mean,
∆ˆma(S) :=
P∑
p=1
P ∗(Mp|y)∆ˆ(p)(S).
The posterior variance can be approximated by
P∑
p=1
[V ar(∆ˆ(p)(S)) + (∆ˆ(p)(S))2]P ∗(Mj|y)− ∆ˆ2ma(S),
which can be used to calculate an uncertainty interval based on a normal approximation
(see also Raftery (1995)).
2.4.3 Resampling
The general idea of the resampling approach is to split the original dataset into an identifica-
tion/selection sample and an estimation sample, so patients are either in the identification
or estimation sample. This allows to estimate the magnitude of over-estimation introduced
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by the selection. Sun & Bull (2005) compare several different resampling approaches. Two
estimators from their paper will be used here. The first tries to estimate the bias due to
the selection process directly (similar methods were discussed by Foster et al. (2011) and
Rosenkranz (2016)) the other being the 0.632-estimator, originally derived for estimation
of the prediction error of classification rules (Efron (1983)), which performed best in the
comparisons of Sun & Bull (2005). Additionally we use a third method, which is a resam-
pling version of the model averaging approach and therefore more similar to the approach
described in the previous section. For this paper we used bootstrap resampling estimators.
If a subgroup S has been identified, the naive estimate for the treatment effect in that
subgroup is ∆ˆnaive(S) and is obtained as described in Section 2.4.1. To obtain adjusted
resampling estimates, B bootstrap samples of size n are drawn from the original dataset and
the identification process is repeated in each of these identification samples. In each of the B
steps the treatment effect for the identified subgroup is estimated using the identification
sample and the out-of-sample patients in the estimation sample, the difference between
these two estimates should give an idea of the bias induced by selection. Note that the
identification in each of the B steps might lead to different subgroups than the one identified
originally on the whole dataset.
The first estimator tries to estimate the selection bias by comparing the estimates
in the identification and estimation samples directly. If ∆ˆ
(I)
naive(S
(b)
I ) denotes the naive
estimate from the b-th identification sample for the subgroup, S
(b)
I , identified in the same
identification sample and ∆ˆ
(E)
naive(S
(b)
I ) denotes the estimate from the b-th estimation sample
for the same subgroup. Then the difference between the two gives an estimate of the
selection bias. Then the estimator for ∆(S) is
∆ˆrsbias(S) := ∆ˆnaive(S)− 1
B
B∑
b=1
[∆ˆ
(I)
naive(S
(b)
I )− ∆ˆ(E)naive(S(b)I )]. (10)
This estimator adjusts the naive estimate by substracting the estimate for the selection
bias.
The 0.632-estimator uses the approximation that on average the sample size in the
estimation sample in each step is nE = 0.368n, since on average 36.8 % of patients do not
appear in the identification sample. The adjusted estimate derived from this combines the
naive estimate with the average estimates in the estimation sample so that the adjusted
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estimate for the originally identified subgroup is
∆ˆrs632(S) := (1− 0.632)∆ˆnaive(S) + 0.632 · 1
B
B∑
b=1
∆ˆ
(E)
naive(S
(b)
I ). (11)
For simplicity, we calculated confidence intervals for these two methods using the intervals
for the naive estimator, but centering it around the bias-adjusted estimates.
The third resampling estimator is motivated by bootstrap model averaging in the sense
of a bagging estimator (Breiman (1996)). For this estimator we use the BIC in each boot-
strap sample to identify the model with the best subgroup/covariate. Then the treatment
effect for the originally identified subgroup S is estimated under this model. We obtain an
estimate for the treatment effect by averaging over the estimates for all bootstrap samples.
If ∆ˆ(b)(S) therefore denotes the estimate of the treatment effect in S from the model Mb,
which was identified as the one with the lowest BIC from all candidate models in the b-th
bootstrap sample, an estimator for the treatment effect in S is given through
∆ˆrsma(S) :=
1
B
B∑
b=1
∆ˆ(b)(S). (12)
Since we have an estimate of the treatment effect for S in each bootstrap sample we can use
the empirical quantiles from these B estimates to calculate a bootstrap confidence interval
for the treatment effect in the subgroup.
2.4.4 Lasso Regression
The models described in Section 2.2 are all marginal models, in the sense that they only
include one covariate/subgroup at a time in each model. An alternative to fitting several
marginal models is fitting a single multivariate model, which includes prognostic and pre-
dictive effects for all covariates. As it is expected that only a small number of covariates
will have an effect on the response and the treatment effect, it makes sense to use penalized
regression methods.
Lasso regression as presented by Tibshirani (1996) is maybe the most commonly used
penalized regression method. Penalization is achieved by adding a penalty to the log-
likelihood function, so instead of maximizing the log-likelihood alone the penalty term
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λ
∑K
j=1|βj| is added, which induces shrinkage towards 0, the parameter λ controls the
shrinkage.
For the Lasso estimates we hence use only one model, including all covariates. In the
notation of the general modeling approach (1) we use the terms
h(xi.) =
K∑
k=1
βk+1 · xik
g(xi.) =
K∑
k=1
βK+k+1 · xik.
The R package glmnet (Friedman et al. (2009)) was used to estimate the Lasso model.
We did not add a penalty on the parameter for the overall effect (β1 in model (1)), since the
treatment effect estimates in identified subgroups should be shrunken towards the overall
treatment effect but not below it. Therefore only the parameters in the prognostic and
predictive terms g and h were included in the penalty. We chose the shrinkage parameter
λ that minimised the average cross validation error over 10 10-fold cross validations using
the cv.glmnet function, since choosing the λ on a single 10-fold cross validation was found
to be too variable for smaller sample sizes.
Based on this model a predicted treatment effect δˆi for patient i can be obtained as
in Equation (4). An estimator for the treatment effect in subgroup S based on the Lasso
model is therefore given by the average of the predicted treatment effects of patients in the
subgroup as
∆ˆlas(S) :=
1
|S|
∑
i∈S
δˆi, (13)
where δˆi = βˆ
(L)
1 +
∑K
m=1 βˆ
(L)
K+m+1 · xim, and βˆ(L)1 , βˆ(L)K+m+1 are the estimates determined by
the Lasso. Note that a few of the βˆ
(L)
K+m+1 will be estimated to be exactly 0. In the extreme
case, where all of the βˆ
(L)
K+m+1 will be zero, Lasso will predict the same treatment effect for
every patient. To come up with a confidence interval again the naive interval is re-centered
around this adjusted estimate (as for ∆ˆrs632 and ∆ˆrsbias).
Note that the Lasso approach is performed here not to identify a subgroup, just to
obtain the treatment effect for the already determined subgroup (by either the step function
or spline approach). Contrary to the model averaging and resampling approaches it is
independent of the models that are used for identification.
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3 Simulation Setup
In this section we will describe how we set up the simulation study. Two subgroup identi-
fication methods were used and six methods for estimating treatment effects (see Table 1
for an overview), giving 12 methods to evaluate in total. We used R (R Core Team (2015))
for simulations. For all scenarios we ran 5000 simulations with B=100 bootstrap samples.
Table 1: Estimators used in simulations
estimation method (estimator) denoted by
naive (∆ˆnaive) naive
model averaging (∆ˆma) ma
0.632-estimator (∆ˆrs632) rs632
resampling with model averaging (∆ˆrsma) rsma
resampling bias adjustment (∆ˆrsbias) rsbias
lasso (∆ˆlas) Lasso
3.1 Data Generation
The covariate vectors x.1, ..., x.K are generated from independent standard normal distri-
butions for each patient. The outcome variable yi is generated from the covariates using
the model
yi = Ti · g(xi1) + i, i = 1, ..., n, (14)
where the i are i.i.d standard normally distributed. This means that the response mean
under the control group is 0, in addition there are no prognostic covariates that have an
effect on the outcome independent of the treatment. The treatment effect depends on the
first covariate and is described by the function g. The model above implies that the overall
average treatment effect, which we will denote here by ∆(Ω) is given by
∆(Ω) =
∫ ∞
−∞
g(x) · fN(0,1)(x)dx,
where fN(0,1)(x) is the density of the standard normal distribution.
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3.2 Simulation Parameters
Table 2 gives an overview of the different parameters varied in the simulation study.
Table 2: Parameter settings varied in the simulations.
parameter abbreviation settings
sample size n 50, 500
number of covariates K 5, 10, 30
effect size delta large (power=0.9), small (power=0.5), zero
treatment effect curve curve step function, linear, sigmoidal
For the sample size n of the trial, we chose to use n = 50 and n = 500. A sample size
of n = 50 could be considered representative of an early Phase II trial (a Proof-of-Concept
(PoC) trial). These trials are usually the first trials with patients. The aim of a Proof of
Concept-trial is to determine, whether there is enough evidence for the treatment effect
of a drug to warrant further development. If this is the case, the drug will be developed
further. In this scenario interest often also lies on finding potential groups of patients, that
respond differently to the drug, in particular if the overall treatment effect is not promising
enough. The second sample size of n = 500 is more representative of a small Phase III
study. As discussed in the introduction, exploratory analyses are also routinely conducted
in this later phase of drug development.
The treatment effect in the overall population is another parameter that is varied across
the simulations. Three different effect sizes are used in the simulation study. First we
consider a ”zero” scenario of no overall treatment effect and no subgroup. In the other
two scenarios there is an overall treatment effect. The overall effect sizes are based on
the power they would give a two-sample t-test (with significance level 5% two-sided) to
show a significant treatment effect on the overall population. The two power values used
in this simulation study are 0.9 and 0.5, we will in the following denote this by “large” and
“small” overall treatment effects. The first scenario covers the situation, where the sample
size is sufficient to reliably detect the overall treatment effect. The second scenario covers
the situation, where the sample size is too small to detect the overall treatment effect, and
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only in a subgroup a promising treatment effect exists (but the sample size in the subgroup
is too small to detect the effect).
The functional form of the interaction between covariates and treatment, which de-
termines how the treatment effect is distributed across patients, can have an influence
on subgroup identification and subgroup effect estimation. Hence in this simulation study
three different forms of g are used, modelling the treatment effect depending on the first co-
variate. The three forms are a step function, a linear function and a curve with a sigmoidal
form. The corresponding equations to these forms of g are
gstep(x) = bstep · 1(0,∞)(x)
glin(x) = alin + blin · x
gsig(x) = asig + bsig · erf(x)
where erf(x) = 2√
pi
∫ x
0
e−τ
2
is the error function and the specific intercept and slope pa-
rameters, a and b are chosen so that an overall average treatment effect ∆(Ω) is achieved,
in addition it is required that the average treatment effect for patients i with xi1 > 0 is
given by 2 ·∆(Ω). This second condition guarantees that there are subgroups with higher
than average treatment effects. Given these conditions we can determine a and b for all
functions g, see Appendix B and Table 3.
Table 3: Overall treatment effects and parameter values for the different treatment effect
functions. For glin and gsig the intercept a is equal to the overall effect.
settings overall step linear sigmoidal
n = 50, power=0.9 0.94 b=1.88 b = 1.17 b=1.54
n = 50, power=0.5 0.57 b=1.14 b = 0.71 b=0.48
n = 500, power=0.9 0.29 b=0.58 b = 0.36 b=1.07
n = 500, power=0.5 0.18 b=0.36 b = 0.22 b=0.29
See Figure 1 for a graphical display of the different functions. For covariate values
x1 < 0 patients have a treatment effect smaller than the overall treatment effect in all
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Figure 1: Different types of (non-zero) treatment effect curves used in the simulation study
for sample size n = 100 and power 0.9, the dashed line shows the corresponding overall
treatment effect of 0.65.
cases. For the linear and sigmoidal function the response even gets worse than the control
response mean (which is 0). This is not unreasonable to assume, when considering that an
active control might be used in the trial.
Another important parameter is the number of covariates K that are used to identify
possible subgroups. We chose K=5, 10 and 30. Clearly it is expected that a higher number
of covariates makes correct subgroup identification, as well as treatment effect estimation
more difficult, since the possibility of chance findings increases.
4 Simulation results
We simulated 5000 datasets under each combination of simulation parameters. For each
of the datasets we identified the best subgroup with the simple identification strategy
described in Section 2.3, choosing the model with the lowest p-value for the interaction
test.
We then estimate the treatment effect for the identified subgroup (which is not nec-
essarily the correct one) using all estimators shown in Table 1. The main performance
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metrics considered are the bias, MSE and the coverage probability of 90% confidence in-
tervals calculated as described in Section 2. We use median biases and MSEs, since the
estimates obtained with the spline approach were prone to contain outliers.
We briefly present the differences between the two modeling approaches in subgroup
identification performance and then turn to the results for treatment effect estimation,
which is the main part of our work.
4.1 Performance of Subgroup Identification Methods
Figure 2 summarizes the performance of the two identification approaches in different sce-
narios for 10 covariates. Results for the remaining two settings for the number of covariates
are shown in the supplementary material.
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Figure 2: Relative frequency of correct identifications for the spline and step function
modeling approaches. An identification is considered as correct, when there is a true
interaction between the identified covariate and the treatment. In all depicted scenarios
the number of covariates was 10.
The step function approach identifies the correct covariate with a similar or even higher
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percentage than the spline approach in all scenarios with an existing subgroup. The differ-
ence is largest, when the true treatment effect curve is a step function. If the true treatment
effect curve is either linear or sigmoidal the difference between the two methods is smaller,
as expected as in this case the step functions models are misspecified. It is nevertheless
interesting that even in those scenarios step functions outperform the splines, we will return
to this point in the discussion.
4.2 Simulation Results for Effect Estimation in Subgroups
In this section we only show the bias, MSE and confidence interval coverage for a sample
size of n = 50 and for a true step function treatment effect curve. Results for the larger
sample size and other functional forms of treatment effect curves were similar and are
shown in the supplementary material. The results for the bias of the different estimators
are shown in Figure 3, MSE results are depicted in Figure 4 and coverage of confidence
intervals is depicted in Figure 5.
One general observation is that the biases in Figure 3 tend to get larger the smaller the
treatment effect in the true subgroup is. This is because the chances to identify the correct
subgroup are naturally higher, if the effect in that subgroup is big (see also Section 4.1).
For small effects the found subgroup is more likely to be a chance finding.
The naive estimates overestimate the true treatment effects, especially, when the effect
in the true subgroup is only small or there is no subgroup and effect. The bias also
increases for a higher number of covariates. Comparing the two modeling approaches, the
spline method seems to result in slightly better naive estimates, since the biases are usually
a bit smaller.
The ma-, rsma- and rs632-estimators all behave similarly and have smaller biases than
the naive estimates. For large effect sizes these three estimators tend to have a slight
negative bias, while the bias is positive, but smaller than the naive estimate, when effects
are small or zero. An additional observation for the ma-estimator is that the bias for spline
models seems to be slightly bigger than for step-function models. An intuitive explanation
for this result, is that using model averaging with spline models does not properly account
for the uncertainty in the selection of the subgroup cut-off, since cut-offs are determined
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Figure 3: Median bias of estimators for the step function (top row) and spline modeling
approaches. Scenarios with differing number of covariates K and effect sizes delta in the
true subgroup are depicted. For all depicted scenarios n = 50 and curve = step.
after choosing the best model.
The Lasso estimator has a small bias, when the effect size in the true subgroup is
small or there is no subgroup at all. Generally it has a more negative bias than all of the
estimators described before for the case of a large effect size.
The rsbias estimator shows very large biases and always underestimates the true effect,
even if the true effect is zero, which means that it gives estimates that lie below the overall
treatment effect.
For the MSE (Figure 4) the results are similar to the results for the bias. The MSEs for
the naive estimates are higher than for most of the other estimators, but are smaller for the
spline method than for the step functions. The ma- rsma-, rs632 and Lasso-estimators have
smaller MSEs than the naive estimates. When the effect in the subgroup is small or there
is no subgroup at all, the Lasso-estimator has the smallest MSE of all estimators evaluated
here. The rsbias-estimator again performs poorly and has sometimes worse MSEs than the
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Figure 4: Median MSE of estimators for the step function (top row) and spline modeling
approaches. Scenarios with differing number of covariates K and effect sizes delta in the
true subgroup are depicted. For all depicted scenarios n = 50 and curve = step.
naive estimates.
In terms of confidence interval coverage (Figure 5), the naive estimates are always below
the nominal level, sometimes even dropping below 50%, when there is no subgroup and
the number of covariates is high. The rsbias estimator is also always below the nominal
coverage. The calculated confidence intervals for the remaining estimators generally have
good properties (in particular rsma, rs632, and ma) and usually have a coverage around
the nominal level.
5 Further Simulations Investigating Asymptotic Be-
haviour
In this section we evaluate the influence of certain simulation parameters on the estimates
given by the different methods, going beyond the scenarios shown in Table 2, in particular
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Figure 5: Average coverage of 90%-confidence intervals of estimators for the step-function
(top row) and spline modeling approaches. Scenarios with differing number of covariates K
and effect sizes delta in the true subgroup are depicted. For all depicted scenarios n = 50
and curve = step.
K, n and delta were varied.
These simulations aim to show the asymptotic behaviour of the estimates for the true
subgroup as the evidence a subgroup effect gets stronger and stronger (or weaker). One
specific question that these simulations tried to answer was, if the correct subgroup is
known, how big does the evidence have to be, that the estimation method will give an
estimate that is reasonably close to the naive (and in this case true) treatment effect. In
short, when do the methods stop shrinking?
In addition we considered the situation that covariates are no longer generated inde-
pendently, but are correlated with an AR(1)-correlation structure. Since correlation did
not seem to influence the estimates, results for correlated covariates are not depicted here
and can be found in the supplementary material.
For the simulations in this section the subgroup identification process was omitted and
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instead the subgroup S = {i ∈ {1, ..., n}|xi1 > median(x.1)} was always chosen. The step
function models were used for estimation and the true treatment effect curve also had the
form of a step function. Unless one of the parameters was changed explicitly the sample
size was n = 500 the overall average treatment effect was 0.29, which results in an overall
power of 0.9, and the number of covariates was K = 10. Since a step function curve was
used the true effect in the subgroup S was 0.58 (see Table 3).
Results of these simulation runs are shown in Figure 6 for the three parameters n, K
and delta. Depicted are the averaged estimates over 5000 simulations. The sample size n
(Figure 6 (i)) seems to affect all estimates similarly, bringing them closer to the true effect
as the sample size grows. In general all estimates apart from the Lasso seem to approach
the true estimates as the sample size increases. The Lasso estimator seems to approach a
value for the treatment effect, which lies a good amount below the true effect.
As it is visible from Figure 6 (ii) a higher number of covariates shrinks the estimates
towards the overall effect. The ma-estimator and to a lesser amount the rsma- and rs632-
estimators still remain close to the naive estimates even for a high number of covariates,
as desired. The Lasso-estimator and especially the rsbias-estimator are more heavily af-
fected by a high number of covariates. The rsbias-estimator even shrinks below the overall
treatment effect.
In Figure 6 (iii) the effect size delta in the subgroup was modified. Similar to Figure 6
(i) all estimators except the Lasso approach the true effect as the effect size grows.
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Figure 6: Influence of simulation parameters n (i), K (ii) and delta (iii) in the subgroup on
different estimators for the subgroup x1 > median(x1). The standard scenario is n = 500,
K = 10, theta = 0 and a large effect size in the subgroup (0.58). The treatment effect
curve has the form of a step function and the models using step functions are used.
25
6 Discussion
The purpose of this paper was to compare several methods for treatment effect estimation
in subgroup analyses in a simulation study. We also considered the effect of categorizing
covariates compared to modelling continuous covariates with splines.
One main conclusion to be drawn from the simulations in Section 4.2 is that naive es-
timation methods (ignoring model uncertainty/subgroup selection) will lead to inadequate
inference: Treatment effects in selected subgroups will be over-estimated and confidence
intervals will not have the nominal level. In addition we have shown that a few methods
outperform the naive estimate in our scenarios: both in terms of bias and MSE of esti-
mate but also in terms of confidence interval coverage, promising methods appear to be
the model averaging (ma and rsma) approaches, the 0.632 bootstrap estimate (rs632) as
well as the Lasso approach. The naive bias adjustment method (rsbias) based on directly
estimating the bias caused by selection and subtracting it from the naive estimate, did not
perform very well.
From the simulation results it seems that model averaging, resampling and Lasso are
all viable candidates to adjust treatment effect estimates. In what follows we will compare
these methods from a conceptual and computational perspective.
The adjustments induced by the model averaging approaches (ma, rsma) and the Lasso
approach do not explicitly depend on the selection mechanism itself. These methods induce
shrinkage in the treatment effect estimate from their underlying modelling assumptions.
The resampling approaches (rsbias, rs632) depend on the specific selection mechanism, in
the sense that different adjustments would be derived for different selection mechanisms.
This also means that the ma, rsma and Lasso approach can be used to derived adjusted
treatment effect estimates essentially for all subgroups S one is interested in (this itself
could also be utilized as a subgroup selection strategy). The resampling approaches can
only make a statement about the actually selected subgroup. Finally the treatment effect
estimates for a particular subgroup derived with the ma, rsma and Lasso approaches are
only based on patients in that subgroup, while the adjustments in rsbias and rs632 are also
based on patients not in the selected subgroup.
From a computational perspective the resampling methods are significantly more bur-
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densome, since subgroup identification has to be repeated in every bootstrap sample. For
reference, estimation with resampling using 100 bootstrap samples took approximately 80
times longer than estimation with model averaging and approximately 20 times longer than
estimation with lasso on our machine.
Even though the focus of our work was treatment effect estimation we also got some
insight into the effect of categorizing covariates through our simulations. For determining
the right covariate (defining the subgroup), it turned out that the step-function approach
worked quite well compared to a spline-based approach (see Section 4.1). This is probably
due to difficulty to estimate the splines model reliably with the relatively high variance (low
signal to noise ratio) in the endpoint, even though a low dimensional basis was used (see
Appendix A). Working with rank-transformed covariates improved the performance of the
splines, in particular by reducing the variability at the end-points of the covariate space.
P-splines (Eilers & Marx (1996)) or fractional polynomials (Royston & Sauerbrei (2004)),
might further improve the situation, as the complexity of the model-fit is adaptively chosen
by these methods (by using shrinkage or model selection). Of course, when it comes to
estimation of the treatment effect curve g(x) itself in an unweighted way the spline based
approach might outperform the step-function approach, a metric we did not consider in
this form in this paper. However, in our results naive estimation improved, when basing it
upon splines.
For identification of subgroups we chose the group, which maximized standardized dif-
ference between treatment effect estimates (see Section 2.3). This implicitly penalizes
towards groups of equal size. Alternatively one could also pick the subgroup to maximize
the treatment effect difference (omitting the standardization by the standard error of the
difference): The simulations from Sections 4.1 and 4.2 were also run with this identification
rule. Results were however mostly unaffected by this change, noticeable was only a small
improvement in correct identifications when using step functions.
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Appendix A Knot Selection Rules
We use quantiles to select the knots. We roughly follow the guidelines given by Harrell (2001).
Compared to the original proposal less knots are selected to obtain less variable spline estimates.
We base the number of knots on the number of patients in the treatment group and then use the
same number of knots for the prognostic term h and for the predictive term g. The knots used
for different sample sizes in this simulation study are shown in Table A1.
Table A1: Number and placement of knots for natural cubic splines for different number
of patients in the treatment arms, x(i) denotes the i-th ordered observation of x
patients in trt number of knots placement of knots
n≤ 10 1 median
10 < n ≤ 20 2 x(5), x(n−4)
20 < n ≤ 30 3 x(5), median, x(n−4)
n ≥ 30 4 x(5), 0.35-quantile, 0.65-quantile, x(n−4)
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Appendix B Obtaining Treatment Effect Curve Pa-
rameters
The overall treatment effect under model (14) is given by
∫∞
−∞ g(x) · fN(0,1)(x)dx. Now we desire
that a specific overall treatment effect holds for the population:
∫∞
−∞ g(x) · fN(0,1)(x)dx = ∆(Ω).
An additional constraint is needed to obtain intercept and slope (a and b) for all functions g.
One possibility is to require that
∫∞
0 g(x) · fN(0,1)(x)dx = 2∆(Ω), i.e. the patients with positive
covariate have an average effect, that is double the overall effect. For the step function gstep this
condition is fulfilled for bstep = 2∆(Ω). The other two functions can be written as g(x) = a+bg˜(x),
so that a and b can be moved out of the integral and
∫∞
−∞ g˜(x) · fN(0,1)(x)dx and
∫∞
0 g˜(x) ·
fN(0,1)(x)dx can be precalculated so that a and b can be obtained by solving the corresponding
linear system of two equations, as for both cases
∫∞
−∞ g˜(x) · fN(0,1)(x)dx = 0, a is equal to the
overall effect, while one needs to solve for b. All solutions are given in Table 3.
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Figure S1: Relative frequency of correct identifications for the spline and step function
modeling approaches. An identification is considered as correct, when there is a true
interaction between the identified covariate and the treatment. In the case of no subgroup
(last row) the correct decision is to not identify any subgroup. In all depicted scenarios the
number of covariates was 5.
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Figure S2: Relative frequency of correct identifications for the spline and step function
modeling approaches. An identification is considered as correct, when there is a true
interaction between the identified covariate and the treatment. In the case of no subgroup
(last row) the correct decision is to not identify any subgroup. In all depicted scenarios the
number of covariates was 30.
2
S1.2 Effect Estimation in Subgroups
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
Models=step, K=5 Models=step, K=10 Models=step, K=30
Models=spline, K=5 Models=spline, K=10 Models=spline, K=30
rsbias
lasso
rsma
rs632
ma
naive
rsbias
lasso
rsma
rs632
ma
naive
−1.0 −0.5 0.0 0.5 −1.0 −0.5 0.0 0.5 −1.0 −0.5 0.0 0.5
Bias
M
et
ho
d
Delta
l
l
l
large
small
zero
Figure S3: Median bias of estimators for the step-function (top row) and spline modeling
approaches. Scenarios with differing number of covariates K and effect sizes Delta in the
true subgroup are depicted. For all depicted scenarios n = 50 and curve = linear
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Figure S4: Median bias of estimators for the step-function (top row) and spline modeling
approaches. Scenarios with differing number of covariates K and effect sizes Delta in the
true subgroup are depicted. For all depicted scenarios n = 50 and curve = sigmoidal
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Figure S5: Median bias of estimators for the step-function (top row) and spline modeling
approaches. Scenarios with differing number of covariates K and effect sizes Delta in the
true subgroup are depicted. For all depicted scenarios n = 500 and curve = step
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Figure S6: Median bias of estimators for the step-function (top row) and spline modeling
approaches. Scenarios with differing number of covariates K and effect sizes Delta in the
true subgroup are depicted. For all depicted scenarios n = 500 and curve = linear
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Figure S7: Median bias of estimators for the step-function (top row) and spline modeling
approaches. Scenarios with differing number of covariates K and effect sizes Delta in the
true subgroup are depicted. For all depicted scenarios n = 500 and curve = sigmoidal
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Figure S8: Median MSE of estimators for the step-function (top row) and spline modeling
approaches. Scenarios with differing number of covariates K and effect sizes Delta in the
true subgroup are depicted. For all depicted scenarios n = 50 and curve = linear
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Figure S9: Median MSE of estimators for the step-function (top row) and spline modeling
approaches. Scenarios with differing number of covariates K and effect sizes Delta in the
true subgroup are depicted. For all depicted scenarios n = 50 and curve = sigmoidal
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Figure S10: Median MSE of estimators for the step-function (top row) and spline modeling
approaches. Scenarios with differing number of covariates K and effect sizes Delta in the
true subgroup are depicted. For all depicted scenarios n = 500 and curve = step
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Figure S11: Median MSE of estimators for the step-function (top row) and spline modeling
approaches. Scenarios with differing number of covariates K and effect sizes Delta in the
true subgroup are depicted. For all depicted scenarios n = 500 and curve = linear
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Figure S12: Median MSE of estimators for the step-function (top row) and spline modeling
approaches. Scenarios with differing number of covariates K and effect sizes Delta in the
true subgroup are depicted. For all depicted scenarios n = 500 and curve = sigmoidal
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Figure S13: Average coverage of 90%-confidence intervals of estimators for the step-function
(top row) and spline modeling approaches. Scenarios with differing number of covariates K
and effect sizes Delta in the true subgroup are depicted. For all depicted scenarios n = 50
and curve = linear
13
Models=step, K=5 Models=step, K=10 Models=step, K=30
Models=spline, K=5 Models=spline, K=10 Models=spline, K=30
0.00
0.25
0.50
0.75
1.00
0.00
0.25
0.50
0.75
1.00
rs
bi
as
la
ss
o
rs
m
a
rs
63
2
m
a
n
a
ive
rs
bi
as
la
ss
o
rs
m
a
rs
63
2
m
a
n
a
ive
rs
bi
as
la
ss
o
rs
m
a
rs
63
2
m
a
n
a
ive
Method
Co
ve
ra
ge
Delta
large
small
zero
Figure S14: Average coverage of 90%-confidence intervals of estimators for the step-function
(top row) and spline modeling approaches. Scenarios with differing number of covariates K
and effect sizes Delta in the true subgroup are depicted. For all depicted scenarios n = 50
and curve = sigmoidal
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Figure S15: Average coverage of 90%-confidence intervals of estimators for the step-function
(top row) and spline modeling approaches. Scenarios with differing number of covariates K
and effect sizes Delta in the true subgroup are depicted. For all depicted scenarios n = 500
and curve = step
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Figure S16: Average coverage of 90%-confidence intervals of estimators for the step-function
(top row) and spline modeling approaches. Scenarios with differing number of covariates K
and effect sizes Delta in the true subgroup are depicted. For all depicted scenarios n = 500
and curve = linear
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Figure S17: Average coverage of 90%-confidence intervals of estimators for the step-function
(top row) and spline modeling approaches. Scenarios with differing number of covariates K
and effect sizes Delta in the true subgroup are depicted. For all depicted scenarios n = 500
and curve = sigmoidal
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S1.3 Influence of Simulation Parameter: Correlation
overall
true effect
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Figure S18: Influence of correlation between covariates theta on different estimators for
the subgroup x1 > median(x1). The standard scenario is n = 500, K = 10, theta = 0
and a large effect size in the subgroup (0.58). The treatment effect curve has the form of
a step-function and the models with step-functions are used.
18
